|
Video: What is a Stock Split?
|
|
Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Co.'s primary product candidate, TP-03, is an investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Co. is developing product candidates to address targeted diseases with unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. According to our TARS split history records, Tarsus Pharmaceuticals has had 0 splits. | |
|
Tarsus Pharmaceuticals (TARS) has 0 splits in our TARS split history database.
Looking at the TARS split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tarsus Pharmaceuticals shares, starting with a $10,000 purchase of TARS, presented on a split-history-adjusted basis factoring in the complete TARS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/19/2020 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$22.00 |
|
End price/share: |
$34.57 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
57.14% |
|
Average Annual Total Return: |
14.05% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$15,714.98 |
|
Years: |
3.44 |
|
|
|
|
|